Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $193,096 - $212,666
2,659 New
2,659 $205,000
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $562,390 - $612,443
-9,084 Closed
0 $0
Q1 2021

May 07, 2021

SELL
$59.34 - $66.74 $47,175 - $53,058
-795 Reduced 8.05%
9,084 $573,000
Q4 2020

Feb 04, 2021

BUY
$57.74 - $65.43 $32,045 - $36,313
555 Added 5.95%
9,879 $613,000
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $32,275 - $35,765
562 Added 6.41%
9,324 $562,000
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $68,634 - $80,240
-1,252 Reduced 12.5%
8,762 $515,000
Q1 2020

Apr 29, 2020

SELL
$46.4 - $67.43 $438,108 - $636,674
-9,442 Reduced 48.53%
10,014 $558,000
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $19,191 - $25,034
390 Added 2.05%
19,456 $1.25 Million
Q3 2019

Nov 05, 2019

BUY
$42.77 - $50.71 $49,228 - $58,367
1,151 Added 6.42%
19,066 $967,000
Q2 2019

Aug 15, 2019

BUY
$44.62 - $49.34 $5,309 - $5,871
119 Added 0.67%
17,915 $812,000
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $559,939 - $667,658
-12,410 Reduced 41.08%
17,796 $837,000
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $13.6 Million - $17.6 Million
-278,736 Reduced 90.22%
30,206 $1.57 Million
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $592,906 - $668,751
10,743 Added 3.6%
308,942 $19.2 Million
Q2 2018

Aug 08, 2018

BUY
$50.53 - $62.98 $1.27 Million - $1.58 Million
25,152 Added 9.21%
298,199 $16.5 Million
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $37,629 - $43,319
628 Added 0.23%
273,047 $17.3 Million
Q4 2017

Feb 07, 2018

SELL
$59.94 - $65.35 $223,576 - $243,755
-3,730 Reduced 1.35%
272,419 $16.7 Million
Q3 2017

Oct 25, 2017

BUY
$55.23 - $63.74 $15.3 Million - $17.6 Million
276,149
276,149 $17.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Doyle Wealth Management Portfolio

Follow Doyle Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Doyle Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Doyle Wealth Management with notifications on news.